(Nisevokitug)Biosimilar Reference Antibody-GS40477 新品

货号：GS40477

Nisevokitug is a human IgG2‑lambda monoclonal antibody designed to target and neutralize transforming growth factor‑beta (TGF‑β). As an IgG2 isotype, it is engineered to have minimal effector functions (e.g., reduced antibody‑dependent cellular cytotoxicity), focusing primarily on ligand blockade. By binding to TGF‑β with high affinity, it prevents the cytokine from interacting with its receptors (TGF‑βRI/II), thereby inhibiting the activation of downstream SMAD‑dependent and non‑canonical signaling pathways. This blockade aims to suppress TGF‑β‑mediated immunosuppression, fibrosis, and tumor progression. It is being developed as a potential therapeutic for TGF‑β‑driven diseases, including advanced solid tumors and fibrotic disorders.